Coherus BioSciences, Inc.

CHRS

US19249H1032

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.04 ^USD	+5.70%		-1.45%	-38.74%

Apr. 24	Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting	CI
Mar. 20	HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating	MT

Coherus Biosciences, Inc. Ratifies Selection of Ernst & Young LLP as the Independent Registered Public Accounting Firm of the Company for Its Fiscal Year Ending December 31, 2022

May 20, 2022 at 05:19 pm EDT

Coherus BioSciences, Inc. ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.

Latest news about Coherus BioSciences, Inc.

Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting	Apr. 24	CI
HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating	Mar. 20	MT
Coherus BioSciences Shares Fall After Workforce Reduction Plan; Q4 Loss	Mar. 14	MT
Transcript : Coherus BioSciences, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Earnings Flash (CHRS) COHERUS BIOSCIENCES Reports Q4 Revenue $91.5M, vs. Street Est of $90.4M	Mar. 13	MT
Coherus BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 13	CI
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
North American Morning Briefing : Stock Futures Hover At Start of Busy Week	Mar. 04	DJ
Coherus BioSciences Completes $170 Million Sale of Ophthalmology Franchise to Sandoz	Mar. 04	MT
Sandoz: acquisition of Cimerli finalized	Mar. 04	CF
Sandoz Completes Purchase of Retinal Disease Medication Cimerli from Coherus BioSciences	Mar. 04	MT
Sandoz Inc. completed the acquisition of CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc..	Feb. 29	CI
Coherus Biosciences, Inc. Appoints Georgia Erbez to Board of Directors	Feb. 22	CI
Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv	Feb. 21	CI
KKR to acquire a stake in health tech firm Cotiviti	Feb. 14	RE
BioPharma Credit to receive partial prepayment of loan	Feb. 06	AN
Coherus BioSciences, Inc. Amends Term Loan Agreement with Pharmakon Advisors, LP	Feb. 05	CI
Baird Cuts Coherus BioSciences' Price Target to $9 From $11, Outperform Rating Maintained	Jan. 23	MT
Truist Securities Cuts Coherus BioSciences' Price Target to $8 From $12, Maintains Buy Rating	Jan. 23	MT
Swiss Equities Rally as Rate Decisions, Economic Data Take Center Stage	Jan. 22	MT
Correction: Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Jan. 22	MT
Correction: Sector Update: Health Care	Jan. 22	MT
Correction: Coherus BioSciences to Sell Cimerli Ophthalmology Business to Sandoz for $170 Million	Jan. 22	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Jan. 22	MT
Sector Update: Health Care	Jan. 22	MT

Chart Coherus BioSciences, Inc.

Duration

Period

More charts

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Coherus BioSciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.04 USD

Average target price

7.8 USD

Spread / Average Target

+282.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COHERUS BIOSCIENCES, INC.	-38.74%	219M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs